---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-092528"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:50:46.786282+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Invivyd Q4 PEMGARDA revenue $17.2M (+31% QoQ); VYD2311 DECLARATION trial fully enrolled, top-line mid-2026

## Summary
- Q4 2025 PEMGARDA net revenue $17.2M (up 25% YoY, 31% QoQ); FY2025 revenue $53.4M vs $25.4M in 2024.
- Cash and equivalents $226.7M at Dec 31, 2025; raised over $200M in 2H 2025.
- FY2025 net loss $52.5M ($0.30/share) vs $169.9M ($1.43/share) in 2024; R&D expenses fell to $38.3M.
- DECLARATION Phase 3 trial for VYD2311 fully enrolled; IDMC allows pregnant/breastfeeding women; top-line data expected mid-2026.
- Appointed Michael Mina, M.D., Ph.D., as CMO; Fast Track designation for VYD2311 granted Dec 2025.

## SEC filing metadata
- accession: 0001193125-26-092528
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/0001193125-26-092528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/d118119d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-092528
- JSON: https://secwatch.observer/filing/0001193125-26-092528.json
- Plain text: https://secwatch.observer/filing/0001193125-26-092528.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.